Senior Executives Highlight Expansions, M&A at the DCAT Member Company Announcement Forum
Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.
DCAT Member Companies take to the podium at DCAT Week
Senior executives from DCAT Member Companies highlighted their companies major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT). Companies reported the latest in expansion plans and mergers and acquisitions (M&A) across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 18th, 2024.
Expansions in biomanfacturing, both biologic-based drug substances and cell and gene therapies, was a major theme. Companies making news announcements in this area included Samsung Biologics, Fujifilm Diosynth Biotechnologies, Evotec, Seqens, and Aragen Life Sciences.
Expansions in manufacturing for small-molecule active pharmaceutical ingredients (APIs), including high-potency APIs, and other specialized APIs, was another key area of investment with several companies announcing expansion plans, recently completed expansions, or soon-to-be-completed expansions. These companies included Cambrex, AGC Pharma Chemicals, Porton, Polpharma API, and ST Pharm.
On the drug-product side, expansions in sterile drug manufacturing/injectables was also an area of investment activity announced at the DCAT Member Company Announcement Forum at DCAT Week. Companies making news in this area included Simtra BioPharma Solutions, Kindeva Drug Delivery, Oncomed Manufacturing, and Adragos Pharma.
Crossing more than one manufacturing area are end-to-end providers, which had expansion news for both drug-substance and drug-product manufacturing. These end-to-end providers included announcements by Thermo Fisher Scientific, Noramco, WuXi STA, CordenPharma, BSP Pharmaceuticals, and Enzene Biosciences.
Details of each company’s announcement can be found below.
Samsung Biologics Provides Update on Billion-Dollar-Plus Biomanufacturing Expansions
Thermo Fisher Scientific Highlights Multiple Expansions: Sterile Drug-Product & Biologics Mfg
Noramco Updates Integration of Acquisition of Cambrex’s Drug-Product Business
Simtra BioPharma Solutions Announces $250-M Expansion of Sterile Fill-Finish Mfg Campus
Fujifilm Diosynth Biotechnologies Updates Multi-Billion-Dollar Biomanufacturing Expansions
CordenPharma Announces Mfg Expansions in Peptides, Solid Dosage Products & LNP
AGC Pharma Chemicals Investing $100-M-Plus To Expand Small-Molecule API, High-Potency API Mfg
Evotec Subsidiary Just-Evotec Biologics Adding New Facility for Continuous Biomanufacturing
ST Pharm Investing $110 M To Expand Oligonucleotide Mfg Capacity
Cambrex Nears Completion of Multi-Year, $100-M Small-Molecule API Expansion
Seqens Enters Cell- & Gene-Therapy Market With Acquisition of CELLforCURE
Porton Expanding Small-Molecule API Manufacturing
BSP Pharmaceuticals Announces Multi-Year, $576-M Expansion for Cytotoxic & Non-Cytotoxic Products
Enzene Biosciences Adding New Facility for Continuous Biomanufacturing
Oncomed Manufacturing To Commission New Production Line for Syringes
Adragos Pharma Expands Drug-Product Capabilities with Key Acquisitions
Polpharma API Expanding High-Potency API Manufacturing
Aragen Life Sciences Proceeds with Biomanufacturing Expansion
